| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 12/05/2002 | US20020183298 Pharmaceutical and food compositions containing" wood alcohols" or" wood sterols" useful for lowering serum cholesterol |
| 12/05/2002 | US20020183293 Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage |
| 12/05/2002 | US20020183292 For therapy of respiratory tract diseases |
| 12/05/2002 | US20020183291 Use of an aromatase inhibitor selected from exemestane, anastrozole, letrozole and fadrozole in the preparation of a medicament for use in treating gynecomastia in a patient undergoing treatment with antiandrogen |
| 12/05/2002 | US20020183288 Administering to a subject suffering from hyperparathyroidism an amount of active vitamin D formula sufficient to lower or maintain lowered blood parathyroid hormone (PTH) levels |
| 12/05/2002 | US20020183281 For therapy and prophylaxis of disorders that are ameliorated by the inhibition of neuronal monoamine uptake in mammals; disorders including erectile dysfunction, affective disorders, obesity, cerebral function disorders, pain |
| 12/05/2002 | US20020183280 For controlled administration of pharmaceutically active agents to patients, wherein formulation is administered as liquids which thicken to form gels upon instillation into the eye |
| 12/05/2002 | US20020183271 Administering to the patient a human MDA-7 polypeptide or a nucleic acid expressing the human MDA-7 polypeptide in eukaryotic cells, whereby the MDA-7 polypeptide inhibits angiogenesis in the patient |
| 12/05/2002 | US20020183266 Combination comprising combretastatin and anticancer agents |
| 12/05/2002 | US20020183265 Manufacture and use of an antibiotic/antibiotics preparation |
| 12/05/2002 | US20020183264 Use of harpagid-related compounds for prevention and treatment of osteoporosis, arthritis and ruptured disc and pharmaceutical composition containing the same |
| 12/05/2002 | US20020183255 Use of KPV tripeptide for dermatological disorders |
| 12/05/2002 | US20020183250 For use in therapy of sleep disorders |
| 12/05/2002 | US20020183245 For therapy of Porphyromonas (Bacteroides) gingivalis; periodontal disorder |
| 12/05/2002 | US20020183244 Coating endoluminal surface of a tissue by coating with water soluble proteinaceous material and with di- or polyaldehyde; allowing formulation to cure |
| 12/05/2002 | US20020183240 Antineoplastic combinations |
| 12/05/2002 | US20020183239 Administering effective amount of a combination comprising an mTOR inhibitor and an antimetabolite antineoplastic agent for therapy of neoplasm in mammal |
| 12/05/2002 | US20020183237 Methods of performing vagal-induced asystole |
| 12/05/2002 | US20020182725 New antigen presenting cells, a process for preparing the same and their use as cellular vaccines |
| 12/05/2002 | US20020182691 Nucleotide sequences coding transport protein for use in nervous system disorders |
| 12/05/2002 | US20020182681 Peptide for use in treatment of cancer, parkinson's and metabolic disorders |
| 12/05/2002 | US20020182676 Ob receptor and methods for the diagnosis and treatment of body weight disorders, including obesity and cachexia |
| 12/05/2002 | US20020182671 Polypeptide for use in the treatment, diagnosis, and prevention of cell proliferative, autoimmune/inflammatory, neurological and gatrointestinal disorders |
| 12/05/2002 | US20020182655 Method for identifying ligands for G protein-coupled receptors |
| 12/05/2002 | US20020182650 Inhibitors of binding between proteins and macromolecular ligands |
| 12/05/2002 | US20020182643 Detecting preferential ligands in cell; obtain cell, incubate with reporter molecules, detect reporter in cell |
| 12/05/2002 | US20020182614 Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 12/05/2002 | US20020182612 Diagnosing inflammatory defects in humans; obtain nucleotide sequence sample, incubate with probe associated with preferential allele, detect hybridization, hybridization indicates sensitivty to inflammatory defect |
| 12/05/2002 | US20020182272 Methods of treatment of HIV-associated conditions |
| 12/05/2002 | US20020182268 Plant extracts, especially for breast cancer |
| 12/05/2002 | US20020182251 Antibiotic(s) preparation with retarding active ingredient release |
| 12/05/2002 | US20020182227 Treatment of virus using chelator and antiviral agent |
| 12/05/2002 | US20020182217 Time release chelators |
| 12/05/2002 | US20020182216 Eliciting a T-cell mediated immune response in an animal, comprising administering to the animal an extract of an egg comprising transfer factor generated by said source animal |
| 12/05/2002 | US20020182214 Tumor associated internalizing antigens and methods for targeting therapeutic agents |
| 12/05/2002 | US20020182205 Administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site. |
| 12/05/2002 | US20020182204 Combination of a taxane and a cyclin-dependent kinase |
| 12/05/2002 | US20020182187 Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment |
| 12/05/2002 | US20020182185 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| 12/05/2002 | US20020182177 Methods and compositions for promoting the maturation of monocytes |
| 12/05/2002 | US20020182176 Methods and compositions for promoting the maturation of monocytes |
| 12/05/2002 | US20020182175 Administration of a reactive oxygen species (ROS) inhibitor or scavenger (a histmine or its salt, ester, prodrug and agonist) and at least one monocyte maturation promoting agent (a cytokine) |
| 12/05/2002 | US20020182174 Methods and compositions for promoting the maturation of monocytes |
| 12/05/2002 | US20020182162 Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth |
| 12/05/2002 | US20020182156 Contacting the melanocyte with a melanin synthesis inhibiting amount of a fatty acid synthase (FAS) inhibitor (such as cerulenin) to reduce melanin synthesis in the melanocyte |
| 12/05/2002 | CA2614902A1 Metering and packaging of controlled release medication |
| 12/05/2002 | CA2614899A1 Metering and packaging of controlled release medication |
| 12/05/2002 | CA2487014A1 A method of improving the growth performance of an animal |
| 12/05/2002 | CA2449245A1 Small molecule antagonists of bcl2 family proteins |
| 12/05/2002 | CA2449160A1 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| 12/05/2002 | CA2449017A1 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore |
| 12/05/2002 | CA2449009A1 Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
| 12/05/2002 | CA2449006A1 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| 12/05/2002 | CA2449000A1 Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis |
| 12/05/2002 | CA2448956A1 Anti-ngf antibodies for the treatment of various disorders |
| 12/05/2002 | CA2448627A1 Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol |
| 12/05/2002 | CA2448567A1 Modulators of nucleic acid ligands |
| 12/05/2002 | CA2448528A1 Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment |
| 12/05/2002 | CA2448363A1 Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
| 12/05/2002 | CA2448362A1 B7 related protein-2 molecules and uses thereof |
| 12/05/2002 | CA2448320A1 Ribozyme based treatment of female reproductive diseases |
| 12/05/2002 | CA2448148A1 Carbohydrate-associated proteins |
| 12/05/2002 | CA2448146A1 Secreted proteins |
| 12/05/2002 | CA2448116A1 Molecules for disease detection and treatment |
| 12/05/2002 | CA2448104A1 Wnv core protein/capsid interacting protein and uses of the same |
| 12/05/2002 | CA2448086A1 An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases |
| 12/05/2002 | CA2447662A1 Transporters and ion channels |
| 12/05/2002 | CA2447657A1 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease |
| 12/05/2002 | CA2447648A1 Pharmaceutical combinations |
| 12/05/2002 | CA2447475A1 Hydantion derivatives as inhibitors of matrix metalloproteinases |
| 12/05/2002 | CA2446723A1 Antibodies that immunospecifically bind to trail receptors |
| 12/05/2002 | CA2446613A1 A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases |
| 12/05/2002 | CA2445650A1 Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways |
| 12/05/2002 | CA2445611A1 P-cadherin as a target for anti-cancer therapy |
| 12/05/2002 | CA2443713A1 Proteins associated with cell growth, differentiation, and death |
| 12/05/2002 | CA2411549A1 Ligands of integrin receptors |
| 12/05/2002 | CA2411082A1 Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament |
| 12/04/2002 | EP1262490A1 GPib-LIPID BOND CONSTRUCT AND USE THEREOF |
| 12/04/2002 | EP1262197A2 Combination treatment for sleep disorders including sleep apnea |
| 12/04/2002 | EP1262196A2 Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence |
| 12/04/2002 | EP1262185A1 Synergistic antibiotic compositions |
| 12/04/2002 | EP1262184A1 Compositions comprising S-tofisopam and use of these compositions for the preparation of a medicament for the treatment or prevention of convulsions or seizures |
| 12/04/2002 | EP1262183A1 Use of norastemizole for the treatment of allergic rhinitis |
| 12/04/2002 | EP1262176A1 Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| 12/04/2002 | EP1262175A2 Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality |
| 12/04/2002 | EP1261744A2 Estrogen receptor beta variants and methods of detection thereof |
| 12/04/2002 | EP1261711A2 Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| 12/04/2002 | EP1261707A1 5ht3 receptors of nematodes, polynucleotide molecules encoding same, and antagonists thereof |
| 12/04/2002 | EP1261706A2 Egg specific surface proteins |
| 12/04/2002 | EP1261700A2 Cis acting regulatory nucleic acid sequences in the parathyroid hormone 3'-untranslated region |
| 12/04/2002 | EP1261643A1 Composition for inhibiting macrophage activity |
| 12/04/2002 | EP1261639A2 Chondromodulin-i related peptide |
| 12/04/2002 | EP1261638A2 Human fgf-23 gene and gene expression products |
| 12/04/2002 | EP1261636A2 Human protein kinases and protein kinase-like enzymes |
| 12/04/2002 | EP1261586A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv, processes for their preparation, and their use |
| 12/04/2002 | EP1261374A2 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| 12/04/2002 | EP1261373A2 Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions |
| 12/04/2002 | EP1261372A2 Method of treating cancer with anti-neurotrophin agents |
| 12/04/2002 | EP1261371A1 Membrane estrogen receptor-directed therapy in breast cancer |
| 12/04/2002 | EP1261370A1 Therapeutic method for reducing angiogenesis |